Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CardioComm SolutionsEKGGF EV-to-EBITDA is -3.74 as of Sep. 03, 2026. The stock has 8 warning signs investors should review. Among 515 Healthcare Providers & Services companies, CardioComm Solutions ranks worse than 194174.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CardioComm Solutions's enterprise value is $1.17 Mil.
CardioComm Solutions's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.31 Mil. Therefore, CardioComm Solutions's EV-to-EBITDA for today is -3.74.
The historical rank and industry rank for CardioComm Solutions's EV-to-EBITDA or its related term are showing as below:
EKGGF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1305.05 Med: -8.07 Max: 598.42
Current: -3.78
During the past 13 years, the highest EV-to-EBITDA of CardioComm Solutions was 598.42. The lowest was -1305.05. And the median was -8.07.
EKGGF's EV-to-EBITDA is ranked worse than 100% of 515
companies
in the Healthcare Providers & Services industry
Industry Median: 10.43
vs EKGGF: -3.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CardioComm Solutions's PE Ratio (TTM) for today is calculated as:
CardioComm Solutions's share price for today is $0.01.
CardioComm Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CardioComm Solutions's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, CardioComm Solutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CardioComm Solutions EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CardioComm Solutions's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CardioComm Solutions's EV-to-EBITDA falls into.
CardioComm Solutions's current Enterprise Value is $1.17 Mil.
CardioComm Solutions's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CardioComm Solutions (EKGGF) has a EV-to-EBITDA of -3.74 as of Sep. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CardioComm Solutions. According to the industry distribution chart, CardioComm Solutions ranks #999999 out of 515 companies in the Healthcare Providers & Services industry.
Is CardioComm Solutions' EV-to-EBITDA too high?
CardioComm Solutions' current EV-to-EBITDA is -3.74. Based on the distribution chart, CardioComm Solutions ranks #999999 out of 515 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does CardioComm Solutions' EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, CardioComm Solutions ranks #999999 out of 515 companies for EV-to-EBITDA. This places CardioComm Solutions in the lower half of its industry. The industry median EV-to-EBITDA is 10.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.43, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CardioComm Solutions. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CardioComm Solutions's current EV-to-EBITDA is -3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CardioComm Solutions stock overvalued right now?
CardioComm Solutions (EKGGF) has a current EV-to-EBITDA of -3.74. The current EV-to-EBITDA is -3.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CardioComm Solutions (EKGGF), the current EV-to-EBITDA is -3.74 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CardioComm Solutions Inc develops software, hardware and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. The Company has one operating segment, which involves the development of software and the sale of ECG recording equipment and ECG reading services for the cardiology field. Substantially all the Company's operations, assets, and employees are in Canada. Revenue is earned in Canada and the United States. Its products are GEMS Sirona, GEMS WIN, Trident Pro 40L, HeartCheck CardiBeat - Mobile ECG Device, HeartCheck SMART Monitoring, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKGGF has been successfully added to your 
